Vietnam Approves SpaceX Starlink Satellite Internet Service Amid U.S. Trade Talks 
BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer 
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid 
Freedom Finance and Binance Join Forces in Digital Assets 
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
Anthropic’s Claude AI Reportedly Used in U.S. Operation to Capture Nicolas Maduro 
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy 
Bain Capital Secures RBI Approval to Acquire Up to 41.7% Stake in Manappuram Finance 
Luxury Stocks Face Volatility as AI Market Swings and Hedge Fund Bets Rattle LVMH and Kering 
Santos Wins Court Case Over Net Zero and Sustainability Claims 
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
Treasury Wine Estates Profit Falls 46% as China and U.S. Inventory Reset Weighs on Earnings 
Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase 
India AI Impact Summit 2026: Global Tech CEOs Join World Leaders in New Delhi 
Goldman Sachs Reportedly Drops Diversity Criteria From Board Candidate Evaluations 
Macquarie-Led Consortium to Acquire Qube Holdings in A$11.7 Billion Deal 
Anduril Industries Seeks $8 Billion Funding at $60 Billion Valuation 
CAMBRIDGE, Mass., April 27, 2018 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will webcast presentations from its Investor Day, including first quarter financial results, on Friday, May 4, 2018 at 8:00 a.m. ET in New York.
Presentations will be given by members of Agios' leadership team and external speakers including:
- David Schenkein, M.D., Chief Executive Officer
- Scott Biller, Ph.D., Chief Scientific Officer
- Chris Bowden, M.D., Chief Medical Officer
- Andrew Hirsch, Chief Financial Officer and Head of Corporate Development
- Steve Hoerter, Chief Commercial Officer
- Darrin Miles, Vice President, IDH Program Management
- Susan Pandya, M.D., Senior Medical Director, Clinical Development
- Kevin Marks, Ph.D., Senior Director, Head of Cancer Biology
- Maeve Lowery, M.B., B.Ch., B.A.O, Trinity College Dublin
A live webcast of the presentations can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. The presentations are scheduled to begin at 8:00 a.m. ET and conclude at 12:00 p.m. ET. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has an approved oncology precision medicine and multiple first-in-class investigational therapies in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.
Investors:
Renee Leck, 617-649-8299
Senior Manager, Investor Relations
[email protected]
Media:
Holly Manning, 617-844-6630
Associate Director, Corporate Communications
[email protected]
